Each year on the 28th of July, people around the world come together to mark World Hepatitis Day. One of the World Health Organization’s nine global public health days, its aim is to raise awareness of the global burden of viral hepatitis and to galvanise the attention, energy and resources needed to take action.
In 2022, the theme of the event is ‘Hepatitis Can’t Wait’, drawing attention to the urgency of global efforts to eliminate hepatitis B and C. For almost three years now, COVID-19 has been at the centre of our attention, and this has impacted other public health issues, including viral hepatitis. Given COVID-19 remains ongoing, this year’s World Hepatitis Day campaign is aimed at encouraging us to turn our attention (back) to urgent global action on viral hepatitis. This includes Australia, which is pursuing an ambitious national goal of eliminating hepatitis C by 2030.
To mark the event, researchers from ARCSHS got together with the CEO of Hepatitis Australia Carrie Fowlie to share and discuss findings from three recent social research projects on hepatitis C. These projects cover a range of issues relating to hepatitis C in Australia in the age of viral elimination, including:
- People’s lived experiences of treatment for hepatitis C;
- Experiences of telehealth care delivery for hepatitis C; and
- The post-cure lives and needs of people treated for hepatitis C.
The discussion was hosted by Associate Professor Kate Seear, Research Lead of the Gender, Law and Drugs (GLaD) program at ARCSHS, and was chaired by GLaD researcher Dr Dion Kagan. It featured contributions from Dr Adrian Farrugia, a member of the Drugs, Gender and Sexuality (DruGS) team at ARCSHS, GLaD researchers Emily Lenton and Dr Sean Mulcahy, and Dr Renae Fomiatti, from the School of Humanities and Social Sciences at Deakin University, and an Adjunct Research Fellow at ARCSHS.